SCYNEXIS begins Phase 1 trial of intravenous SCY-247 antifungal therapy
Tweet Send to a Friend
SCYNEXIS Inc. (NASDAQ: SCYX) announced that the first participants have been dosed in a Phase 1 single ascending dose and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


